Untitled 3

Source R&D is the authoritative source of technology and services information supporting pharmaceutical and biotechnology companies in their drug discovery and development research projects.

Source R&D features extensive listings of service providers classified under company or organisation type, including contract chemical manufacturers; contract biologics manufacturers; biological research companies and organisations; and companies and organisations providing advisory, consultancy, legal, regulatory and other services.

The extensive coverage of Source R&D and the support of life sciences organisations One Nucleus and Bionow make it an invaluable reference tool that streamlines the vendor selection process to bring pharmaceutical/biotechnology companies and suppliers together.

First in-vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018

TxCell logo 10.7.18CTRI logo 3.8.18

Dr Carole Guillonneau, of the Center of Research in Transplantation and Immunology (CRTI) in Nantes, France has presented proof-of-concept preclinical data generated by TxCell and CRTI at the annual meeting of the Federation of Clinical Immunology Societies (FOCIS 2018) in San Francisco, USA in June.

Entitled ‘Cell therapy with engineered HLA-A2 specific CAR-CD8+ Tregs to avoid transplant rejection’, the presentation is the first to deliver data obtained by TxCell and CRTI with proprietary CD8+ CAR-Tregs (HLA-A2 CAR-Tregs) in relevant animal models of graft-versus-host disease and skin graft.

In these models, CD8+ CAR-Tregs showed a significant impact on mice survival and delay of skin graft rejection vs control. It was also demonstrated that the transduction of a CAR into a CD8+ Treg cell had no impact on the cell phenotype nor on the Treg function, notably its suppressive activity.

“These new proof-of-concept data demonstrate the progress TxCell and CRTI have made since the start of their collaboration only 12 months ago,” said François Meyer, PhD, Chairman of the Board and Head of Research at TxCell. “TxCell now has three CAR-Treg platforms supported by encouraging data. This makes us a clear leader in this emerging field. We expect to start soon the development in humans of the first of these platforms, the CD4+ CAR-Treg platform, with TX200, our lead CAR-Treg programme targeting HLA-A2 for the prevention of chronic rejection after organ transplantation. TxCell will continue in parallel to invest in its earlier stage CD8+ Treg and Tr1 platforms. This will give the best chance to TxCell to select the most appropriate approach for patients in areas of significant unmet medical need.”

For further information about TxCell visit www.txcell.com and for further information about CTRI visit www.itun.nantes.inserm.fr

Last modified onFriday, 03 August 2018 07:39